ArticleScientific reports2025
A cytometric bead array for the measurement of plasma biomarker levels in patients with Alzheimer's disease.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diagnostic performance of plasma p-tau217 levels measured with different assays for Alzheimer's disease.Translational psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Identifying plasma biomarkers for Alzheimer's disease (AD) has garnered strong interest. In this study, a cytometric bead array (CBA) method for measuring the levels of amyloid-β (Aβ) peptides and phosphorylated tau (P-tau) was evaluated. Fifty patients with cognitive impairment (CI) and 22 cognitively unimpaired (CU) controls were recruited. CI patients were classified into Aβ + and Aβ - groups according to amyloid positron emission tomography (PET) scan results. Biomarker levels in the plasma of all participants and in the cerebrospinal fluid (CSF) of 28 CI patients were measured via CBA. Plasma P-tau181 levels were greatest in the Aβ + CI group and showed excellent performance in differentiating Aβ + CI patients from CU controls. The plasma and CSF levels of P-tau181 were correlated with each other and had similar diagnostic performance for distinguishing between Aβ + CI patients and Aβ- CI patients. Overall, CBA is a potential cost-effective method for measuring plasma biomarkers, particularly P-tau181, in AD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.